期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 86, 期 3, 页码 628-636出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2021.06.017
关键词
alopecia; arthritis; atopic dermatitis; confounders; conjunctivitis; dupilumab; facial dermatitis; facial erythema; psoriasis; treatment failure
类别
Atopic dermatitis is a chronic inflammatory skin disease, and dupilumab is the only approved systemic therapy for moderate-to-severe cases. Limited literature is available on treatment failure with dupilumab, and individual goals and quality of life should be considered. Possible confounding dermatoses should be ruled out.
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by pruritus, skin pain, and sleep disturbances. Currently, dupilumab is the only systemic therapy and biologic medication approved by the United States Food and Drug Administration for moderate-to-severe AD in adults and children. There is a sparsity of literature available on determining treatment failure with dupilumab and the next steps health care providers can take to treat AD. Individual goals and quality of life and not just body surface area should be considered when defining treatment failure. Possible confounding dermatoses also should be ruled out. Early identification of dupilumab-induced adverse events is important. For most patients, dupilumab can be continued while treatment for the adverse event is initiated. Adjusting the frequency of dupilumab dosing also may be considered in some circumstances. Adjuvant therapies, such as methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, or phototherapy can be added but the safety and efficacy of these combination treatments are not known at this time.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据